Business
Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement
The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries.Expanded collaboration provides future co-development opportunities. COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine
About this update from Bavarian Nordic A/s
[{"type":"image","alt":"Bavarian Nordic A/S","displaySize":"","headline":null,"caption":"Bavarian Nordic A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":224,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X7d037B4FI93H1mEWMcPsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0","width":224,"height":118}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries.","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded collaboration provides future co-development opportunities.","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":192,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs). This agreement builds on the existing mpox vaccine license and manufacturing agreement with SII, and replaces the agreement previously entered with Biological E. Limited.","length":627,"tagName":"p"},{"type":"text","content":"In addition, through this expanded collaboration, the parties will explore potential future co-development opportunities.","length":121,"tagName":"p"},{"type":"text","content":"“We are pleased to strengthen our strategic partnership with Serum Institute of India. By leveraging the strengths of both organizations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe,” said Paul Chaplin, President & CEO of Bavarian Nordic.","length":328,"tagName":"p"},{"type":"text","content":"About CHIKV VLPCHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIK...